DK2402005T3 - Formuleringer med langvarig frigivelse af nalbuphin - Google Patents

Formuleringer med langvarig frigivelse af nalbuphin Download PDF

Info

Publication number
DK2402005T3
DK2402005T3 DK11178912.9T DK11178912T DK2402005T3 DK 2402005 T3 DK2402005 T3 DK 2402005T3 DK 11178912 T DK11178912 T DK 11178912T DK 2402005 T3 DK2402005 T3 DK 2402005T3
Authority
DK
Denmark
Prior art keywords
nalbuphine
sustained
release formulations
formulations
release
Prior art date
Application number
DK11178912.9T
Other languages
English (en)
Inventor
Anand Baichwal
Thomas Sciascia
Donald Diehl
Brian Vogler
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2402005T3 publication Critical patent/DK2402005T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
DK11178912.9T 2005-08-24 2006-08-24 Formuleringer med langvarig frigivelse af nalbuphin DK2402005T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71077205P 2005-08-24 2005-08-24
US77246606P 2006-02-10 2006-02-10
EP06789964.1A EP1931315B1 (en) 2005-08-24 2006-08-24 Sustained release formulations of nalbuphine

Publications (1)

Publication Number Publication Date
DK2402005T3 true DK2402005T3 (da) 2021-03-15

Family

ID=37772363

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11178912.9T DK2402005T3 (da) 2005-08-24 2006-08-24 Formuleringer med langvarig frigivelse af nalbuphin
DK06789964.1T DK1931315T3 (da) 2005-08-24 2006-08-24 Depotformuleringer af nalbufin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06789964.1T DK1931315T3 (da) 2005-08-24 2006-08-24 Depotformuleringer af nalbufin

Country Status (10)

Country Link
US (2) US8771732B2 (da)
EP (2) EP2402005B1 (da)
JP (1) JP2009506059A (da)
CA (2) CA2881739C (da)
DK (2) DK2402005T3 (da)
ES (2) ES2862573T3 (da)
HU (1) HUE053838T2 (da)
PL (2) PL2402005T3 (da)
PT (2) PT1931315E (da)
WO (1) WO2007025005A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452874A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
DK1931346T3 (da) * 2005-09-09 2012-10-22 Angelini Labopharm Llc Trazodonsammensætning til indgivelse en gang om dagen
CN101827590A (zh) * 2007-10-16 2010-09-08 莱博法姆公司 用于持续释放对乙酰氨基酚和曲马多的双层组合物
CA2707980C (en) 2007-12-17 2015-05-12 Labopharm Inc. Misuse preventative, controlled release formulation
JP2011530529A (ja) * 2008-08-07 2011-12-22 アバントール パフォーマンス マテリアルズ， インコーポレイテッド ゴムおよび糖アルコールを含む徐放性組成物
JP5667575B2 (ja) 2008-12-16 2015-02-12 パラディン ラブス インコーポレーテッド 誤用を防止する放出制御製剤
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
CA2834735C (en) 2011-04-29 2021-06-01 University Of Medicine And Dentistry Of New Jersey Use of nalbuphine for treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
EP2931279B1 (en) * 2012-12-14 2024-03-20 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
RU2017101102A (ru) * 2014-06-13 2018-07-16 Треви Терапьютикс, Инк. Способы лечения зуда
JP2017100971A (ja) * 2015-11-30 2017-06-08 株式会社ファンケル 錠剤
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
CN112703000A (zh) * 2018-07-23 2021-04-23 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4282215A (en) 1980-06-17 1981-08-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
US4407805A (en) 1982-06-30 1983-10-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and zomepirac
US4407804A (en) 1982-06-30 1983-10-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and indomethacin
US4404210A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and ibuprofen
US4404211A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and flurbiprofen
US4404209A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and sulindac
US4404208A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
US4402962A (en) 1982-06-30 1983-09-06 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4720384A (en) 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
DE69427551T2 (de) 1993-03-15 2002-05-16 Nat Science Council Taipeh T A Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5750534A (en) 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6225321B1 (en) 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NZ517559A (en) 1999-08-31 2004-08-27 Gruenenthal Chemie Sustained release pharmaceutical composition containing tramadol saccharinate
EP1207852A4 (en) 1999-09-02 2009-11-11 Nostrum Pharmaceuticals Inc ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
ATE376414T1 (de) 1999-09-02 2007-11-15 Nostrum Pharmaceuticals Inc Pellet formulierung mit gesteuerter freisetzung
IL143375A0 (en) * 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
ES2188481T3 (es) 2000-04-27 2003-07-01 Oliver Yoa-Pu Hu Derivados de polinalbufina.
AU2001268353A1 (en) 2000-06-09 2001-12-17 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
US6703398B2 (en) 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
AU2003261298A1 (en) * 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
JP4865330B2 (ja) 2002-12-13 2012-02-01 デュレクト コーポレーション 経口ドラッグデリバリーシステム
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ATE454169T1 (de) 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
CA2541371C (en) 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
EP1584335A3 (en) 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain

Also Published As

Publication number Publication date
EP2402005A1 (en) 2012-01-04
DK1931315T3 (da) 2014-01-20
CA2881739C (en) 2018-01-02
WO2007025005A2 (en) 2007-03-01
US8771732B2 (en) 2014-07-08
PT1931315E (pt) 2014-01-03
JP2009506059A (ja) 2009-02-12
US20070048376A1 (en) 2007-03-01
WO2007025005A3 (en) 2007-12-21
EP1931315B1 (en) 2013-10-16
US20140315937A1 (en) 2014-10-23
CA2620224A1 (en) 2007-03-01
EP1931315A2 (en) 2008-06-18
US9186330B2 (en) 2015-11-17
ES2441766T3 (es) 2014-02-06
ES2862573T3 (es) 2021-10-07
HUE053838T2 (hu) 2021-07-28
PL1931315T3 (pl) 2014-09-30
PT2402005T (pt) 2021-04-14
EP2402005B1 (en) 2020-12-16
CA2881739A1 (en) 2007-03-01
CA2620224C (en) 2015-11-24
PL2402005T3 (pl) 2021-11-22

Similar Documents

Publication Publication Date Title
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1778618T3 (da) Syntese af triethylentetraminer
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1858342T3 (da) Fremgangsmåde til fremstilling af ernæringssammensætninger
DK1720866T3 (da) Fremgangsmåde
CY2013035I1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
DK3395339T3 (da) Hurtigt opløsende formulering af cinacalcet-hcl
DK1937071T3 (da) Krystallinske modifikationer af pyraclostrobin
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1879844T3 (da) Fremstilling af natriumdiformiat
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
NO20055643D0 (no) Preparation of lodixanol
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
CR9144A (es) Formulaciones de benzoxazoles sustituidos
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1963251T3 (da) Fremgangsmåde til fremstilling af aminer
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
NO20043305D0 (no) Preparation of lodixanol
MA28698B1 (fr) Dicetopiperazines substituees utilisees comme antagonistes des oxytocines
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
DK2253619T3 (da) Aminsalt af carbostyrilderivat
DK1888613T3 (da) Fremgangsmåde til fremstilling af thiophenglycosidderivater